Urology & Renal
Medicines

Urology & Renal Medicine Supply for Hospitals & International Buyers

Urological and renal conditions represent a significant and growing disease burden across GCC countries and Africa. Benign prostatic hyperplasia (BPH) affects a large proportion of men over 50, while chronic kidney disease (CKD) and end-stage renal disease (ESRD) are rising sharply due to high rates of diabetes and hypertension in the Gulf region. Dialysis centres are expanding rapidly in Saudi Arabia, the UAE, Qatar and across sub-Saharan Africa, driving sustained demand for renal medicines. Euro Biom works with NHS urology departments, renal units, private clinics and international healthcare buyers to supply these medicines reliably.

BPH treatment relies on alpha-1 adrenoceptor blockers and 5-alpha reductase inhibitors. Euro Biom sources tamsulosin, alfuzosin, doxazosin and terazosin across multiple oral formulations, as well as finasteride and dutasteride as monotherapy and in combination products. These medicines are required in high volumes across GCC hospital pharmacies and outpatient urology clinics, and consistent UK-sourced supply provides a reliable alternative when regional distribution networks are disrupted.

Overactive bladder and urinary incontinence are managed with antimuscarinic agents and beta-3 adrenoceptor agonists. Euro Biom supplies oxybutynin, tolterodine, solifenacin, darifenacin and trospium, as well as mirabegron for patients who cannot tolerate antimuscarinics. These medicines are widely prescribed in both hospital and community urology settings, and demand from international buyers has grown as ageing demographics in GCC countries drive greater awareness and treatment uptake.

Erectile dysfunction medicines are among the most consistently requested products from international buyers in the GCC and Africa. Euro Biom supplies PDE5 inhibitors including sildenafil, tadalafil, vardenafil and avanafil in both branded and generic forms. Where branded products are preferred by hospital formularies, or where generic supply is restricted in a specific market, UK-licensed supply via Euro Biom provides a compliant and quality-assured route to access.

Renal Transplant, Dialysis and CKD Medicines

Urinary tract infections (UTIs) are a high-volume indication requiring reliable antibiotic supply. Euro Biom sources nitrofurantoin, trimethoprim, fosfomycin and pivmecillinam for acute UTI treatment, as well as low-dose prophylactic regimens used in recurrent UTI management. These products are required consistently by hospital infection teams and urology departments managing catheter-associated and recurrent UTIs.

Renal transplant programmes in the GCC and Africa depend on uninterrupted immunosuppression supply. Euro Biom sources tacrolimus, ciclosporin, mycophenolate mofetil and sirolimus, which are the primary agents used to prevent organ rejection. Tacrolimus in particular requires careful formulation-specific sourcing, and Euro Biom can supply both immediate-release and prolonged-release formulations from UK-licensed manufacturers.

Dialysis-dependent patients require a range of supportive medicines to manage the consequences of renal failure. Euro Biom supplies erythropoiesis-stimulating agents (ESAs) including epoetin alfa, epoetin beta and darbepoetin for renal anaemia, alongside intravenous iron preparations such as ferric carboxymaltose. Phosphate binders (sevelamer, calcium carbonate, lanthanum carbonate), the calcimimetic cinacalcet and calcitriol for renal bone disease are also within our range.

Medicines targeting proteinuria and CKD progression are an expanding area of supply. ACE inhibitors and angiotensin receptor blockers (ARBs) are standard of care for reducing proteinuria in diabetic and non-diabetic CKD. More recently, sodium-glucose cotransporter-2 (SGLT2) inhibitors including dapagliflozin and empagliflozin have demonstrated significant renoprotective effects and are now widely used in CKD management. Euro Biom holds a UK Wholesale Dealer Authorisation (WDA) and operates under Good Distribution Practice (GDP), enabling compliant export of these medicines to licensed importers across the GCC and Africa.